252 related articles for article (PubMed ID: 31466222)
1. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
2. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
3. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
4. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
Muñoz M; Rosso M; Coveñas R
Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
[TBL] [Abstract][Full Text] [Related]
5. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
Muñoz M; Coveñas R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
[TBL] [Abstract][Full Text] [Related]
6. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
7. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M; Coveñas R
Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
[TBL] [Abstract][Full Text] [Related]
8. Involvement of substance P and the NK-1 receptor in pancreatic cancer.
Muñoz M; Coveñas R
World J Gastroenterol; 2014 Mar; 20(9):2321-34. PubMed ID: 24605029
[TBL] [Abstract][Full Text] [Related]
9. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
Muñoz M; Rosso M; Coveñas R
Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
[TBL] [Abstract][Full Text] [Related]
10. Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.
Isorna I; González-Moles MÁ; Muñoz M; Esteban F
J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835053
[TBL] [Abstract][Full Text] [Related]
11. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
Muñoz M; Coveñas R
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962202
[TBL] [Abstract][Full Text] [Related]
12. The NK-1 receptor: a new target in cancer therapy.
Muñoz M; Rosso M; Coveñas R
Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668
[TBL] [Abstract][Full Text] [Related]
13. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Munoz M; Covenas R; Esteban F; Redondo M
J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
[TBL] [Abstract][Full Text] [Related]
14. Cancer progression and substance P.
Coveñas R; Muñoz M
Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
[TBL] [Abstract][Full Text] [Related]
15. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
Munoz M; Recio S; Rosso M; Redondo M; Covenas R
J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
[TBL] [Abstract][Full Text] [Related]
16. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Muñoz M; Martinez-Armesto J; Coveñas R
Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
[TBL] [Abstract][Full Text] [Related]
17. Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
Muñoz M; Coveñas R
Anticancer Agents Med Chem; 2019; 19(1):92-100. PubMed ID: 29692265
[TBL] [Abstract][Full Text] [Related]
18. Involvement of substance P and the NK-1 receptor in cancer progression.
Muñoz M; Coveñas R
Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients.
Robinson P; Rosso M; Muñoz M
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983138
[TBL] [Abstract][Full Text] [Related]
20. Advances in the research and application of neurokinin-1 receptor antagonists.
Hong X; Ma J; Zheng S; Zhao G; Fu C
J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
